The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

But within weeks, Novo Nordisk’s partnership crumbled amid a messy war of words. Novo Nordisk accused Hims & Hers of continuing to deceptively sell large volumes of copycat vers ...

The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said ...

President Trump on Thursday sent letters to 17 of the world’s biggest drugmakers demanding that they reduce some of their U.S ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. ABC is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO), the Danish ...

Resmed beat Wall Street estimates for fourth-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.